Cargando…
Investigating potential immune mechanisms of trilaciclib administered prior to chemotherapy in patients with metastatic triple-negative breast cancer
PURPOSE: In a phase II trial in patients with metastatic triple-negative breast cancer (mTNBC; NCT02978716), administering trilaciclib prior to gemcitabine plus carboplatin (GCb) enhanced T-cell activation and improved overall survival versus GCb alone. The survival benefit was more pronounced in pa...
Autores principales: | Tan, Antoinette R., O’Shaughnessy, Joyce, Cao, Subing, Ahn, Sarah, Yi, John S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361859/ https://www.ncbi.nlm.nih.gov/pubmed/37418031 http://dx.doi.org/10.1007/s10549-023-07009-8 |
Ejemplares similares
-
Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study
por: Tan, Antoinette R., et al.
Publicado: (2022) -
Overexpressions of Vimentin and Integrins in Human Metastatic Spine Tumors
por: Park, Sung Bae, et al.
Publicado: (2015) -
The hedgehog pathway in triple‐negative breast cancer
por: Habib, Joyce G., et al.
Publicado: (2016) -
Lower expression of Bax predicts poor clinical outcome in patients with glioma after curative resection and radiotherapy/chemotherapy
por: Wang, Pei-Guo, et al.
Publicado: (2018) -
Investigating the Potential of Lipids for Use as Biomarkers for Glioblastoma via an Untargeted Lipidomics Approach
por: Soylemez, Burcak, et al.
Publicado: (2023)